Channel News AsiaBristol-Myers Squibb (BMY) Receives Positive EMA Opinion for Opdivo as ...StreetInsider.comThe European Medicines Agency (EMA) has recommended granting a marketing authorisation for Opdivo (nivolumab). Opdivo is recommended to be used on its own (monotherapy) for the treatment of adult patients with advanced (unresectable or metastatic) ...Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union ...MarketWatchBristol wins EU green light for immune system cancer drugChannel News Asiaall 4 news articles »
